Events I think that could send AstraZeneca shares rallying in 2021

Given the start of 2021, Jay Yao writes what he thinks are events that could send AstraZeneca shares potentially higher this year

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Although AstraZeneca (LSE:AZN) shares didn’t decline in 2020, they haven’t rallied like many other FTSE 100 stocks have in the past three months either. One reason could be that some of the potentially positive events for AZN in 2020 didn’t turn out to be as great as expected. 

Many investors, for example, regarded AstraZeneca’s Covid-19 vaccine as one of the leaders for much of its development phase. When it came to end results, however, AstraZeneca’s Covid-19 vaccine efficacy rate wasn’t as great as Pfizer or Moderna’s.

Fortunately, it’s a new year. With the new year comes new potential events. With that in mind, here are some potential events that I think could send AstraZeneca shares higher.

Important events for AstraZeneca shares in 2021

I reckon 2021 could be an eventful year for AstraZeneca as the company could release numerous phase 3 trial results that could give more information into the value of AZN’s pipeline. If more key assets of AstraZeneca’s pipeline are approved than expected, AZN has the potential to go higher.

This year could also be important as AZN’s Alexion purchase is expected to close in Q3.

Management expects the Alexion purchase to help with profitability and core operating margin in the short term. Management also expects recurring run-rate pre-tax synergies of $500 million by the end of the third year after the deal closes. With this timeline, AstraZeneca management has a chance to show how they are executing on the deal via outlook and potentially Q3/Q4 results. If the merger goes better than expected, I think there is also a chance for AstraZeneca shares to go higher.

Other important AZN events include how much money the company makes from its Covid-19 vaccine if management were to decide on that path. In terms of its Covid-19 vaccine, AZN has committed to not profiting before the ‘pandemic period’, but not after it. According to earlier releases, management has defined the ending of the pandemic period as the start of July of 2021. Another key event could be whether the company’s long acting monoclonal antibody combination for Covid-19 is approved. In terms of the antibody combination, there could be demand from those whose immune system doesn’t respond to traditional vaccines if the combination works well and is approved.

Last but not least, I think the earnings reports of AZN will be important. If the company beats the market estimates, there is potential for a rally in shares.

Would I buy shares?

Long term, I reckon AZN is in a great position. As the speed of developing a Covid-19 vaccine shows, technology is rapidly advancing. While it took several years at the earliest to develop vaccines before, it has now taken just around a year to come up with a vaccine for the pandemic. Pharmaceutical companies like Moderna are more efficient because they have faster computers and more RNA technology experience. Scientists could also potentially use the recent AI-unlocked protein-folding breakthrough to help fight future outbreaks.

Because I think management will harness many of the future technology advancements successfully, I’d buy and hold AstraZeneca shares.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jay Yao has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »